News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,563 Results
Type
Article (19961)
Company Profile (130)
Press Release (312472)
Section
Business (105385)
Career Advice (879)
Deals (18539)
Drug Delivery (97)
Drug Development (50773)
Employer Resources (79)
FDA (7685)
Job Trends (7747)
News (185881)
Policy (17335)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (733)
Accelerated approval (1)
Adcomms (17)
Allergies (38)
Alliances (27831)
ALS (51)
Alzheimer's disease (618)
Antibody-drug conjugate (ADC) (83)
Approvals (7694)
Artificial intelligence (129)
Autoimmune disease (11)
Automation (4)
Bankruptcy (177)
Best Places to Work (5563)
BIOSECURE Act (13)
Biosimilars (90)
Biotechnology (59)
Bladder cancer (28)
Brain cancer (18)
Breast cancer (102)
Cancer (962)
Cardiovascular disease (98)
Career advice (711)
Career pathing (20)
CAR-T (53)
Cell therapy (143)
Cervical cancer (5)
Clinical research (42544)
Collaboration (434)
Compensation (145)
Complete response letters (22)
COVID-19 (1096)
CRISPR (21)
C-suite (131)
Cystic fibrosis (56)
Data (997)
Decentralized trials (2)
Denatured (18)
Depression (23)
Diabetes (133)
Diagnostics (1803)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (71)
Drug pricing (109)
Drug shortages (30)
Duchenne muscular dystrophy (54)
Earnings (38878)
Editorial (29)
Employer branding (10)
Employer resources (73)
Events (48398)
Executive appointments (405)
FDA (8211)
Featured Employer (24)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (292)
Gene editing (45)
Generative AI (17)
Gene therapy (139)
GLP-1 (566)
Government (1833)
Grass and pollen (2)
Guidances (18)
Healthcare (5901)
Huntington's disease (13)
IgA nephropathy (17)
Immunology and inflammation (73)
Indications (17)
Infectious disease (1173)
Inflammatory bowel disease (81)
Inflation Reduction Act (8)
Influenza (24)
Intellectual property (49)
Interviews (116)
IPO (7369)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (20)
Layoffs (271)
Leadership (13)
Legal (4113)
Liver cancer (31)
Lung cancer (144)
Lymphoma (80)
Machine learning (2)
Management (30)
Manufacturing (185)
MASH (44)
Medical device (1959)
Medtech (1962)
Mergers & acquisitions (11395)
Metabolic disorders (459)
Multiple sclerosis (44)
NASH (20)
Neurodegenerative disease (41)
Neuropsychiatric disorders (20)
Neuroscience (896)
NextGen: Class of 2025 (2357)
Non-profit (906)
Northern California (988)
Now hiring (19)
Obesity (288)
Opinion (189)
Ovarian cancer (31)
Pain (63)
Pancreatic cancer (35)
Parkinson's disease (75)
Partnered (9)
Patents (124)
Patient recruitment (44)
Peanut (15)
People (33354)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13318)
Phase II (17998)
Phase III (14465)
Pipeline (578)
Podcasts (67)
Policy (100)
Postmarket research (1618)
Preclinical (4627)
Press Release (29)
Prostate cancer (57)
Psychedelics (16)
Radiopharmaceuticals (160)
Rare diseases (228)
Real estate (3172)
Recruiting (29)
Regulatory (12463)
Reports (21)
Research institute (817)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (1)
RSV (23)
Schizophrenia (55)
Series A (55)
Series B (30)
Service/supplier (6)
Sickle cell disease (34)
Southern California (954)
Special edition (15)
Spinal muscular atrophy (110)
Sponsored (12)
Startups (2008)
State (2)
Stomach cancer (9)
Supply chain (49)
The Weekly (47)
United States (9388)
Vaccines (265)
Venture capitalists (27)
Webinars (11)
Weight loss (230)
Women's health (14)
Worklife (7)
Date
Today (57)
Last 7 days (273)
Last 30 days (1411)
Last 365 days (17142)
2025 (3772)
2024 (17684)
2023 (19649)
2022 (25880)
2021 (26643)
2020 (24871)
2019 (20057)
2018 (15588)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14788)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (408)
Alabama (22)
Alaska (1)
Arizona (61)
Arkansas (8)
Asia (24818)
Australia (3210)
California (2333)
Canada (1045)
China (293)
Colorado (93)
Connecticut (95)
Delaware (66)
Europe (51222)
Florida (400)
Georgia (49)
Idaho (16)
Illinois (229)
India (17)
Indiana (164)
Iowa (2)
Japan (106)
Kansas (59)
Kentucky (17)
Louisiana (1)
Maine (4)
Maryland (349)
Massachusetts (1966)
Michigan (45)
Minnesota (129)
Mississippi (1)
Missouri (26)
Montana (10)
Nebraska (11)
Nevada (15)
New Hampshire (8)
New Jersey (945)
New Mexico (21)
New York (683)
North Carolina (474)
North Dakota (2)
Northern California (988)
Ohio (80)
Oklahoma (5)
Oregon (21)
Pennsylvania (546)
Puerto Rico (10)
Rhode Island (12)
South America (606)
South Carolina (3)
Southern California (954)
Tennessee (38)
Texas (310)
Utah (53)
Virginia (77)
Washington D.C. (41)
Washington State (203)
Wisconsin (19)
332,563 Results for "vifor pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
Policy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
7 min read
Press Releases
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
October 17, 2024
·
4 min read
C-suite
GSK CEO Emma Walmsley Gets Pay Bump To Align With Pharma Peers
One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.
February 27, 2025
·
2 min read
·
Annalee Armstrong
Policy
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
16 min read
Press Releases
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
·
14 min read
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
·
4 min read
·
Annalee Armstrong
Policy
Approval of delisting of Vifor Pharma AG’s registered shares
Vifor Pharma AG announced that Vifor has received approval for the delisting of the totality of Vifor’s registered shares.
October 12, 2022
·
3 min read
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
1 of 33,257
Next
